 Amphotericin high-dose ketoconazole empirical antifungal therapy febrile granulocytopenic cancer patients prospective study high-dose ketoconazole mg/kg day amphotericin mg/kg day empirical antifungal therapy prospective randomized study febrile granulocytopenic cancer patients patients eligible empirical antifungal therapy patients ineligible randomization treatment inability oral medications patients eligible randomization assessable arm study patients proved fungal infections ketoconazole treatment crossover treatment progressive infection conditions patients amphotericin frequency transaminase elevation ketoconazole frequency azotemia amphotericin Bioavailability ketoconazole unpredictable Amphotericin drug choice empirical antifungal therapy granulocytopenic patients whereas lack parenteral formulation ineffectiveness proved mycoses unreliable bioavailability high-dose ketoconazole appropriate compound purpose